Current Report Filing (8-k)
January 11 2021 - 7:17AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C.
20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of earliest event
reported) January 11, 2021
Citius Pharmaceuticals, Inc.
(Exact name of registrant as specified
in its charter)
Nevada
(State or other jurisdiction of incorporation)
333-206903
|
|
27-3425913
|
(Commission File Number)
|
|
(IRS Employer Identification No.)
|
|
|
|
11 Commerce Drive, 1st Floor, Cranford, NJ
|
|
07016
|
(Address of principal executive offices)
|
|
(Zip Code)
|
Registrant’s telephone number, including
area code (908) 967-6677
Check the appropriate box below if the Form 8-K filing
is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
☐
|
Written communications pursuant to Rule 425 under the
Securities Act (17 CFR 230.425)
|
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the
Exchange Act (17 CFR 240.14a-12)
|
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b)
under the Exchange Act (17 CFR 240.14d-2(b))
|
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c)
under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of
the Act:
Title of each class
|
|
Trading Symbol(s)
|
|
Name of each exchange
on which registered
|
Common stock, $0.001 par value
|
|
CTXR
|
|
The Nasdaq Capital Market
|
Warrants to purchase common stock
|
|
CTXRW
|
|
The Nasdaq Capital Market
|
Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2
of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 8.01. Other Events.
On January 11, 2021, we posted an updated
Corporate Presentation on our website at www.citiuspharma.com. A copy of the Corporate Presentation is attached hereto as Exhibit
99.1 and incorporated herein by reference
Item 9.01. Financial Statements and
Exhibits.
SIGNATURE
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
CITIUS PHARMACEUTICALS, INC.
|
|
|
Date: January 11, 2021
|
/s/ Myron Holubiak
|
|
Myron Holubiak
|
|
President and Chief Executive Officer
|
2
Citius Pharmaceuticals (NASDAQ:CTXR)
Historical Stock Chart
From Apr 2024 to May 2024
Citius Pharmaceuticals (NASDAQ:CTXR)
Historical Stock Chart
From May 2023 to May 2024